TEVA FY 2023 Earnings — Teva Pharmaceutical Industries Limited Revenue & Financial Results | Market Cap Arena

TEVATeva Pharmaceutical Industries Limited

$37B

FY 2023 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$15.8B+6.2% YoY

Gross Profit

$7.6B48.2% margin

Operating Income

$433M2.7% margin

Net Income

-$559M-3.5% margin

EPS (Diluted)

$-0.50

Cash Flow

Operating Cash Flow

$1.4B

Free Cash Flow

$842M

Stock-Based Comp.

$121M

Balance Sheet

Total Assets

$43.5B

Total Liabilities

$35.4B

Stockholders' Equity

$7.5B

Cash & Equivalents

$3.2B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$15.8B	$14.9B	+6.2%
Gross Profit	$7.6B	$7.0B	+9.6%
Operating Income	$433M	-$2.2B	+119.7%
Net Income	-$559M	-$2.4B	+77.1%